Core Viewpoint - Jiahe Biotech-B (06998.HK) announced that its drug Lairosili (GB491) has been included in the National Medical Insurance Drug List (2025) released by the National Healthcare Security Administration on December 7, 2025, marking its first inclusion in the national medical insurance drug list [1] Group 1 - Lairosili (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - The new National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The inclusion of Lairosili (GB491) in the medical insurance list is expected to significantly enhance patient accessibility to the drug and reduce their financial burden [1] Group 2 - The company believes that the inclusion in the insurance list will accelerate the commercialization process and market penetration of Lairosili (GB491), further boosting innovation returns [1]
嘉和生物-B(06998.HK)：来罗西利(GB491)纳入国家医保药品目录